BIO P&L Curve
Bio-Rad Laboratories, Inc. (BIO) operates in the Healthcare sector, specifically the Medical - Devices industry, with a market capitalization near $8.13B, listed on NYSE, employing roughly 7,700 people, carrying a beta of 1.08 to the broader market. Bio-Rad Laboratories, Inc. Led by Norman D. Schwartz, public since 1980-02-27.
A profit/loss curve charts the theoretical gain or loss of an options position across a range of underlying prices. It helps traders visualize risk, identify breakeven points, and compare strategies before committing capital.
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Medical - Devices
- Market Cap
- $8.13B
- Employees
- 7.7K
- IPO Date
- 1980-02-27
- CEO
- Norman D. Schwartz
- Beta
- 1.08
At the current $293.23 spot price with 37.7% ATM implied volatility and 17 days to the front expiration, an at-the-money long straddle carries an approximate combined premium near $19.09, producing breakevens at roughly $274.14 and $312.32. Market-implied 1-standard-deviation range extends from $261.54 to $324.92, which sets the relevant P&L evaluation window for most near-term strategies. Payoff diagrams should be rebuilt from the live options chain; the preceding values are illustrative and assume a single at-the-money straddle for reference.
Frequently asked BIO pl curve questions
- What does a BIO ATM straddle cost today?
- Using current BIO pricing (37.7% ATM IV, 17-day front expiration, $293.23 spot), an at-the-money long straddle (long call + long put at the same strike) carries an approximate combined premium near $19.09 per spread. Breakevens land at roughly $312.32 on the upside and $274.14 on the downside. The estimate uses the Brenner-Subrahmanyam approximation for at-the-money options under Black-Scholes.
- How do I read an options P&L curve?
- An options P&L curve plots theoretical position value at expiration (or at any chosen evaluation date) against the underlying price. The X-axis is the underlying price scenario, the Y-axis is position dollar P&L. The shape of the curve tells you the strategy's directional sensitivity, breakeven points, maximum profit and loss levels, and where time decay or volatility shifts will be most impactful. Multi-leg structures combine the curves of the individual legs to produce composite payoff diagrams.
- What's the difference between a P&L curve and a payoff diagram?
- Strictly: a payoff diagram shows option value at expiration (no time premium left), while a P&L curve typically shows position value at any evaluation date (with remaining time premium). The expiration payoff diagram has kinks at the strikes; the early P&L curve is smooth. For directional-vega trades, the early P&L curve also responds to IV shifts that the expiration payoff diagram does not capture - which is why options traders often look at both views.
- Why are illustrative BIO P&L numbers approximate?
- The numbers above use Black-Scholes assumptions (lognormal returns, constant volatility, no early exercise, no dividends). Real-world option prices reflect skew, term structure, jump risk, and (for US-style options) early exercise premium. Use the live options chain for actual quoted bid/ask prices when sizing trades; the values here illustrate magnitude only.